title: A lower dose of intravitreal bevacizumab effectively treats retinopathy of prematurity.
abstract: To determine whether a low dose (0.25 mg/0.01 mL) of intravitreal bevacizumab is effective in the treatment of type 1 retinopathy of prematurity (ROP).
  
  
  
  This prospective, noncomparative, interventional case series included all consecutive infants who received 0.25 mg/0.01 mL of intravitreal bevacizumab for type 1 ROP. Infants were followed for ROP persistence/recurrence until 90 weeks' postmenstrual age.
  
  
  
  A total of 49 eyes of 25 infants (24 bilateral and 1 unilateral) underwent intravitreal injection of a reduced dose (0.25 mg/0.01 mL) of intravitreal bevacizumab. ROP regressed in all eyes. Follow-up continued until 90 weeks' postmenstrual age and showed no recurrences of plus disease or neovascularization.
  
  
  
  All eyes treated with 0.25mg/0.01ml intravitreal bevacizumab showed complete regression, with no recurrence of plus disease or neovascularization. No safety issues were attributable to bevacizumab during the study period.
authors: Fabrabi Eye Research Center, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
authors: Alireza
authors: A
authors: Khodabande
authors: Fabrabi Eye Research Center, Tehran University of Medical Sciences (TUMS), Tehran, Iran. Electronic address: mreza63neusha@gmail.com.
authors: Mohammad Reza
authors: MR
authors: Niyousha
authors: Fabrabi Eye Research Center, Tehran University of Medical Sciences (TUMS), Tehran, Iran.
authors: Ramak
authors: R
authors: Roohipoor
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab / Q000627:therapeutic use*; D005260:Female; D005865:Gestational Age; D006801:Humans; D007231:Infant, Newborn; D058449:Intravitreal Injections; D008297:Male; D011446:Prospective Studies; D012178:Retinopathy of Prematurity / Q000188:drug therapy*; D042461:Vascular Endothelial Growth Factor A
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab